socazolimab + albumin-bound paclitaxel + cisplatin

This is a **combination regimen** composed of the PD-L1 inhibitor **socazolimab** (a humanized IgG1 monoclonal antibody against programmed death-ligand 1), **albumin-bound paclitaxel** (nab-paclitaxel, a solvent-free, protein nanoparticle formulation of paclitaxel designed for improved delivery and reduced hypersensitivity), and **cisplatin** (a platinum-based antineoplastic agent that induces DNA crosslinking to inhibit cancer cell proliferation). This combination has been tested as neoadjuvant therapy for **locally advanced esophageal squamous cell carcinoma (ESCC)**. Socazolimab blocks the interaction between PD-L1 and PD-1 on T cells, thereby suppressing tumor immune evasion and promoting anti-tumor immunity. Nab-paclitaxel disrupts microtubule function, arresting cell division, while cisplatin intercalates with DNA, impeding replication and transcription. The regimen has exhibited promising pathological response and downstaging, with a safety profile consistent with established standards for these drugs[1][3][6].

Brand names

Abraxane

Other names

nanoparticle albumin–bound paclitaxelprotein-bound paclitaxel